The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
Bet your bottom dollar, at least one little redheaded girl will be longing for brighter days in Virginia Beach this weekend. And warmer days after this week’s heavy snow will have a lot of people ...
Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...
Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...